TCT-542 Stenting of Coronary Bifurcation Lesions with Bioresorbable Everolimus-Eluting Scaffolds. Poznan Bifurcation-Absorb Pilot Registry

The study excluded patients with concomitant serious illnesses, those who were unable to receive prolonged dual antiplatelet therapy or required chronic oral anticoagulation therapy. The main clinical study end point was a device-oriented target lesion failure (TLF), defined as the combination of ca...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2015-10, Vol.66 (15), p.B221-B222
Main Authors: Lesiak, Maciej, Araszkiewicz, Aleksander, Lanocha, Magdalena, Grygier, Marek, Pyda, Malgorzata, Skorupski, Wlodzimierz, Mitkowski, Przemyslaw, Iwanczyk, Sylwia, Lesiak, Michal B, Siniawski, Andrzej, Grajek, Stefan
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Angioplasty
Cardiology
Cardiovascular
Cardiovascular disease
Clinical outcomes
Coronary vessels
Heart attacks
Internal Medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study excluded patients with concomitant serious illnesses, those who were unable to receive prolonged dual antiplatelet therapy or required chronic oral anticoagulation therapy. The main clinical study end point was a device-oriented target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2015.08.559